Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.
Schmidl C, Vladimer GI, Rendeiro AF, Schnabl S, Krausgruber T, Taubert C, Krall N, Pemovska T, Araghi M, Snijder B, Hubmann R, Ringler A, Runggatscher K, Demirtas D, de la Fuente OL, Hilgarth M, Skrabs C, Porpaczy E, Gruber M, Hoermann G, Kubicek S, Staber PB, Shehata M, Superti-Furga G, Jäger U, Bock C. Schmidl C, et al. Among authors: gruber m. Nat Chem Biol. 2019 Mar;15(3):232-240. doi: 10.1038/s41589-018-0205-2. Epub 2019 Jan 28. Nat Chem Biol. 2019. PMID: 30692684 Free PMC article.
Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12.
Porpaczy E, Bilban M, Heinze G, Gruber M, Vanura K, Schwarzinger I, Stilgenbauer S, Streubel B, Fonatsch C, Jaeger U. Porpaczy E, et al. Among authors: gruber m. Eur J Clin Invest. 2009 Jul;39(7):568-75. doi: 10.1111/j.1365-2362.2009.02146.x. Epub 2009 Apr 30. Eur J Clin Invest. 2009. PMID: 19453646
Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
Gruber M, Fleiss K, Porpaczy E, Skrabs C, Hauswirth AW, Gaiger A, Vanura K, Heintel D, Shehata M, Einberger C, Thalhammer R, Fonatsch C, Jäger U. Gruber M, et al. Ann Hematol. 2011 Oct;90(10):1131-6. doi: 10.1007/s00277-011-1260-x. Epub 2011 May 27. Ann Hematol. 2011. PMID: 21617923
Growth dynamics in naturally progressing chronic lymphocytic leukaemia.
Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ. Gruber M, et al. Nature. 2019 Jun;570(7762):474-479. doi: 10.1038/s41586-019-1252-x. Epub 2019 May 29. Nature. 2019. PMID: 31142838 Free PMC article.
Evolving understanding of the CLL genome.
Gruber M, Wu CJ. Gruber M, et al. Semin Hematol. 2014 Jul;51(3):177-87. doi: 10.1053/j.seminhematol.2014.05.004. Epub 2014 May 15. Semin Hematol. 2014. PMID: 25048782 Free PMC article. Review.
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Quijada-Álamo M, Hernández-Sánchez M, Alonso-Pérez V, Rodríguez-Vicente AE, García-Tuñón I, Martín-Izquierdo M, Hernández-Sánchez JM, Herrero AB, Bastida JM, San Segundo L, Gruber M, García JL, Yin S, Ten Hacken E, Benito R, Ordóñez JL, Wu CJ, Hernández-Rivas JM. Quijada-Álamo M, et al. Among authors: gruber m. Leukemia. 2020 Jun;34(6):1599-1612. doi: 10.1038/s41375-020-0714-3. Epub 2020 Jan 23. Leukemia. 2020. PMID: 31974435 Free PMC article.
1,108 results